Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control? (original) (raw)

An Update in Incretin-Based Therapy: A Focus on Glucagon-Like Peptide-1 Receptor Agonists

Krystal Edwards

Diabetes Technology & Therapeutics, 2012

View PDFchevron_right

Incretin-based therapies: focus on effects beyond glycemic control alone

Jaime Davidson

Diabetes therapy : research, treatment and education of diabetes and related disorders, 2013

View PDFchevron_right

Incretin-Based Therapies in Type 2 Diabetes Mellitus

chee keong Chia

The Journal of Clinical Endocrinology & Metabolism, 2008

View PDFchevron_right

Incretin based therapies for type 2 diabetes mellitus

Tarik Elhadd

Journal of the Indian Medical Association, 2008

View PDFchevron_right

Incretin-based therapies and their future in Type 2 diabetes mellitus

KURT BOWEN

Therapy, 2011

View PDFchevron_right

Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications

Melva Louisa

The American Journal of Medicine, 2011

View PDFchevron_right

The Incretin Approach for Diabetes Treatment: Modulation of Islet Hormone Release by GLP-1 Agonism

Jens Juul Holst

Diabetes, 2004

View PDFchevron_right

Incretin-based therapies: new treatments for type 2 diabetes in the new millennium

Joan Khoo

Therapeutics and Clinical Risk Management, 2009

View PDFchevron_right

Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits

Richard Bergenstal

Diabetes Care, 2010

View PDFchevron_right

The Role of Incretins on Insulin Function and Glucose Homeostasis

Mette Rosenkilde

Endocrinology, 2021

View PDFchevron_right

The incretin system and its role in type 2 diabetes mellitus

Jens Juul Holst

Molecular and Cellular Endocrinology, 2009

View PDFchevron_right

A Critical Analysis of the Clinical Use of Incretin-Based Therapies

Edwin Gale

Diabetes Care, 2013

View PDFchevron_right

An Overview of Incretin-Based Therapies: Pharmacology and Future Perspectives

Gehan Heeba

Bulletin of Pharmaceutical Sciences. Assiut

View PDFchevron_right

Incretins: Beyond type 2 diabetes

Paresh Dandona

Diabetes, Obesity and Metabolism

View PDFchevron_right

Incretin-based therapies in the treatment of type 2 diabetes — More than meets the eye?

Krzysztof Labuzek

European Journal of Internal Medicine, 2013

View PDFchevron_right

A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 therapies safe?

Peter Butler

Diabetes Care, 2013

View PDFchevron_right

Incretins: their physiology and application in the treatment of diabetes mellitus

Salih Sanlioglu

Diabetes/Metabolism Research and Reviews, 2013

View PDFchevron_right

Next Step in Incretin-Based Therapy: From Single to Dual Agonism

Sayantan Ray

EMJ Diabetes

View PDFchevron_right

Review Article Advances in pharmacotherapy of Type-2 diabetes (Part-2: The incretin mimetics)

Tarik Elhadd

Sudan medical journal

View PDFchevron_right

Incretin-based therapies: can we achieve glycemic control and cardioprotection?

Franca Stedile Angeli

Journal of Endocrinology, 2013

View PDFchevron_right

Balancing Benefits and Risks in Patients Receiving Incretin-Based Therapies: Focus on Cardiovascular and Pancreatic Side Effects

Stepan Svacina

Drug Safety, 2014

View PDFchevron_right

Incretin System: Recent Advances in Glucagon Like Peptide-1 and Dipeptidyl Peptidase-4 Inhibitors

Dr Rameshwar Mahaseth

Journal of Patan Academy of Health Sciences, 2015

View PDFchevron_right

Incretin-Based Therapies

Brandon Gallwitz

Diabetes care, 2009

View PDFchevron_right

Incretin-based therapy in combination with basal insulin: A promising tactic for the treatment of type 2 diabetes

Taner Damci

Diabetes & Metabolism, 2013

View PDFchevron_right

Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes

Jens J U U L Holst

Diabetes Care, 2011

View PDFchevron_right

Therapy in the Early Stage: Incretins

I. Raz

Diabetes Care, 2011

View PDFchevron_right

Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short‐acting and other glucagon‐like peptide‐1 receptor agonists

Riccardo Bonadonna

Diabetes/Metabolism Research and Reviews, 2016

View PDFchevron_right

Separate Impact of Obesity and Glucose Tolerance on the Incretin Effect in Normal Subjects and Type 2 Diabetic Patients

S. Camastra, Arturo Casolaro

Diabetes, 2008

View PDFchevron_right

Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors

Jaime Davidson

Mayo Clinic Proceedings, 2010

View PDFchevron_right

The Role of Endogenous Incretin Secretion as Amplifier of Glucose-Stimulated Insulin Secretion in Healthy Subjects and Patients With Type 2 Diabetes

Burkhard Göke

Diabetes, 2012

View PDFchevron_right